University of Colorado Launches PreView Medical for PC Diagnosis, Treatment

University of Colorado Launches PreView Medical for PC Diagnosis, Treatment
The University of Colorado Anschutz Medical Campus, led by CU Innovations, has partnered with medical technology entrepreneurs Jonathan Gasson and Sharon Lake to form a new company called PreView Medical, which will focus on the development and optimization of new diagnostic procedures and treatments for prostate cancer. PreView Medical’s ClariCore System is based on a patented, clinically proven optical biopsy needle that combines advanced tissue analyses with machine learning. It allows physicians to examine the prostate in real-time for any signs of cancer. The concept of combining tissue spectroscopy — a powerful technique that analyzes the composition of different body tissues — with a biopsy needle for the diagnosis of prostate cancer was originally conceived by a group of researchers at CU Anschutz. With clinical studies showing that the algorithm in the new ClariCore System has high accuracy, PreView Medical’s new technology could lower the need for patients to undergo conventional biopsies. “PreView Medical's disruptive technology could enhance cancer detection in a very efficient and office-based process,” Neal Shore, MD, medical director of the Carolina Urologic Research Center
Subscribe or to access all post and page content.